Chemical Structure : NVP-TAE226
CAS No.: 761437-28-9
Catalog No.: PC-43388Not For Human Use, Lab Use Only.
NVP-TAE226 (TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM, also potently inhibits Pyk2 (IC50=5 nM), 10- to 100-fold less potent against IR, IGF-IR, ALK, and c-Met kinases.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $98 | In stock | |
10 mg | $138 | In stock | |
25 mg | $218 | In stock | |
50 mg | $358 | In stock | |
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
NVP-TAE226 (TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM, also potently inhibits Pyk2 (IC50=5 nM), 10- to 100-fold less potent against IR, IGF-IR, ALK, and c-Met kinases.
TAE226 suppresses the growth and invasion of glioma cells, inhibits extracellular matrix-induced autophosphorylation of FAK Tyr397.
TAE226 also inhibits IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.
TAE226 significantly increases the survival rate of animals in glioma xenograft model.
M.Wt | 468.936 | |
Formula | C23H25ClN6O3 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- |
1. Halder J, et al. Cancer Res. 2007 Nov 15;67(22):10976-83.
2. Liu TJ, et al. Mol Cancer Ther. 2007 Apr;6(4):1357-67.
3. Watanabe N, et al. Clin Cancer Res. 2008 Jul 15;14(14):4631-9.
4. Sakurama K, et al. Mol Cancer Ther. 2009 Jan;8(1):127-34.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright